ReviewThe Journal of investigative dermatology2026
Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell-Mediated Autoimmune Diseases.
Review in The Journal of investigative dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges.International journal of molecular sciences · 2026Review
- Temporal outcomes and biomarkers of rituximab treatment response in pemphigus: Validation of a historical control dataset.JID innovations : skin science from molecules to population health · 2026Article
- Unraveling the autoimmune architecture of pemphigus: from B-cell depletion to network-based immune engineering.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pemphigus vulgaris (PV) is a B-cell-mediated autoimmune blistering disease characterized by autoantibodies targeting skin cell adhesion proteins. Despite the well-defined pathophysiology and unmet need for safe and effective therapies for pemphigus, multiple therapeutics have failed to advance through clinical development. Prednisone and rituximab are clinically approved for PV, but the neonatal Fc receptor inhibitor efgartigimod and Bruton's tyrosine kinase inhibitor rilzabrutinib failed to receive clinical approval in pemphigus, despite success in other autoantibody-mediated diseases. Conversely, the success of rituximab for PV has not been reproduced for several other B cell-mediated autoimmune diseases. We review learnings from the successes and failures of rituximab, efgartigimod, and rilzabrutinib across B-cell-mediated autoimmune diseases and compare trial designs and endpoints to identify key issues affecting clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.